Efficacy and safety of cilazapril, a new angiotensin-converting enzyme inhibitor.
Cilazapril (CIL), a new angiotensin-converting enzyme inhibitor, was evaluated for 16 weeks in 29 patients with mild to moderate essential hypertension (diastolic pressure 95 mm Hg to 115 mm Hg). Twenty-four patients (83%) normalized their blood pressure (BP) (diastolic pressure less than 90 mm Hg), 11 with low-dose CIL, six with high-dose CIL, one with high-dose CIL plus low-dose thiazide, and six with high-dose CIL and high-dose thiazide. Three withdrew because of side effects (fatigue, bloating, and polyuria). Statistically significant reductions in sitting and standing systolic and diastolic pressures occurred at 8 and 16 weeks on CIL. There was no change in standing or sitting heart rate, white blood cell count, creatinine clearance, urine protein levels. This is the first long-term data on this new converting enzyme inhibitor in human beings.
Goldszer
R C
RC
Department of Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Rodriguez
R
R
Solomon
H S
HS
D000450:Aldosterone / Q000097:blood / Q000652:urine; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001581:Benzothiadiazines; D001794:Blood Pressure; D017315:Cilazapril; D004232:Diuretics; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D011724:Pyridazines / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D012083:Renin / Q000097:blood; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D001581:Benzothiadiazines; D004232:Diuretics; D011724:Pyridazines; D049993:Sodium Chloride Symporter Inhibitors; D017315:Cilazapril; D000450:Aldosterone; D012083:Renin